Application progress of recombinant human endostatin in the treatment of head and neck cancer / 口腔疾病防治

@#The main treatment of head and neck cancer is comprehensive sequential treatment, but the 5-year overall survival rate is less than 50%. Strategies to further improve the curative effect of head and neck cancer are urgently needed in the clinic. Recombinant human vascular endostatin is an antiangiogenesis drug targeting vascular endothelial cells, which has a certain inhibitory effect on tumors. The treatment of malignant tumors by drugs alone is not significantly better than chemoradiation, but combined with radiotherapy and chemotherapy, it can increase the effect of radiotherapy and chemotherapy without drug resistance by changing the distribution of blood vessels, reducing oxygen and normalizing blood vessels. Head and neck tumor treatment has certain advantages. New tumor treatments are expected. The results of a literature review showed that the mechanism of action of recombinant human endostatin mainly includes regulating the matrix protein inside and outside the endothelial cells to influence neovascularization, acting on receptors related to the surface of endothelial cells, reversing abnormal neovascularization to achieve vascular normalization, inhibiting hypoxia inducible factor to improve the hypoxic status of the tumor area, and regulating the cell cycle to ensure the tumor cells are sensitive to radiation in the sensitive period, and vascular normalization can increase the effect of radiotherapy. This treatment has a good synergistic effect with radiotherapy and chemotherapy of head and neck tumors and has a good effect on advanced head and neck tumors.

Combined immunodeficiency / 中华实用儿科临床杂志

Combined immunodeficiency (CID) is categorized to the first classification from the international union of immunological societies expert committee for primary immunodeficiency.Severe combined immunodeficiency (SCID) is the most fatal disorder for paediatric clinical operation.Without hematopoietic stem cell transplantation,almost all infants would die before 1 year old,few could survive beyond 2 years old.Hypomorphic mutations in SCID genes can lead to atypical phenotypes.The two special SCID should be focused,Omenn syndrome and graft-versus-host disease,which are caused by expension of autologous and maternal activated and memory T lymphocytes,respectively.Patients with radiosensitive-CID usually present later on life,for whom treatment should be monitored carefully.CID caused by T cells with normal development and inborn error was hotspot research field for example zeta chain-associated protein 70 kDa deficiency.More attention should be paid to CID associated with syndromes for example dedicator of cytokinesis 8 deficiency.Now,the pathogenesis,molecular,clinical,laboratory features and treatment and prognosis are described,in order to support clues for paediatrician's clinical practice.

Radiation induced expression of HMGB1 in the cells with different radiosensitivity / 中华放射医学与防护杂志

Objective To investigate the effect ot ionizing radiation (IR) on the expressions of HMGB1 in the radiation-sensitive and radiation-resistant human cervical cancer cells and to analysis the role of HMGB1 in the regulation of radiosensitivity.Methods Human cervical cancer cells HeLa and its radioresistant strain HeLaR cells were irradiated with different doses of X-rays.The cells were collected at different time points after irradiation.The expressions of protein and mRNA of HMGB1 were detected by Western blot and real-time quantitative PCR.Results At the protein level,the expression of HMGB1 in HeLaR cells was significantly reduced at 6-36 h after 2,5 and 10 Gy X-ray irradiation (t =3.574-9.754,P ＜0.05),and then it was recovered to the control level at 48 h after IR.On the contrary,the expression of HMGB1 in HeLa cells was significantly increased at 6,12,48 h after 2 Gy IR (t =3.945-4.864,P＜0.05),at 6,36,48hafter5 GyIR (t=-2.875-3.295,P＜0.05),and at 36,48 h after 10 Gy IR (t =-4.480,-4.517,P ＜ 0.05).At mRNA level,the trend of HMGB1 expression alteration was consistent with that of protein expression.Conclusions The changes of HMGB1 expression can be differently induced by X-rays in the human cervical cancer radiation-sensitivity cells and radiation-resistant cells.HMGB1 may be involved in the radioresistance of human cervical cancer.

Comparison analysis of radiosensitive in different subsets of pancreatic adenocarcinoma PANC-1 cell line / 重庆医学

Objective To investigate the radiosensitivity of stem cells in pancreatic adenocarcinoma PANC‐1 cell line and the possible mechanism of its radiation resistance .Methods Using flow cytometry ,the cells were isolated and sorted into CD44+CD24+ ,CD44-CD24+ ,CD44+CD24- ,and CD44-CD24- .Multi‐target click model was used to fit cell survival curves and deter‐mine the sensitizer enhancement ratio .The apoptosis and cycle distribution of the four cell subsets were determined using flow cy‐tometry ,and the level of ROS was determined by DCFH‐DA probe .Results The ratio of CD44+ and CD24+ in the sorted PANC‐1 cell line was 92 .0% and 4 .7% respectively .Before radiation ,there was no statistically significant difference between four groups (P>0 .05);After treated with 6MV‐X ray ,The ratio of apoptosis was the lowest in CD44+CD24+ (P<0 .01);The percentage G0/G1 cell was the highest in CD44+CD24+ (P<0 .01) ,the sensitizer enhancement ratio of CD44+ CD24- ,CD44-CD24+ and CD44-CD24- were 1 .61 ,1 .81 ,1 .94 ,respectively .The level of ROS in CD44+CD24+ was lower (P<0 .01) .Conclusion Tumor stem cells of pancreatic adenocarcinoma have properties of a lower level of ROS and relative stationary that maybe the reasons of radio resist‐ance .

STUDY ON SENSITIZING OF PRE-OPERATIVE RADIOTHERAPY USE HPD FOR SQUANOUS CELL CARCINOMA IN HEAD AND NECE / 中华放射肿瘤学杂志

This paper reports the sensitizing effect of Hematoporphyrin Derivative (HPD) to Radiotherapy (RT) and long survival rates of 28 patients were treated by HPD 5mg/kg iv+D T31Gy/10f/12d+Surgery with squamous cell carcinoma in head and neck. The result was compared with 33 patients who received routine preoperative radiotherapy D T40Gy/20f/26d without HPD.The total HPD group were 44.4%(13/28) of this patients failed to evidence of living tumour cell within surgical specimens. 59.09%(13/22) of patients with the tumour diameter of 4cm in HPD group. The control group was 9.1% only (P

THE EXPERIMENT STUDY OF THE RADIOSENSITIVE EFFECT OF THE GERMANIUM GLUCONATE ON THE MOUSE WITH LEWIS LUNG CANCER / 中华放射肿瘤学杂志

0.05);the TAV of the drug plus radiation dose of 20,25Gy groups were much smaller than that of the radiation alone groups (P